Summary
Dystonic movements
Types of infantile dystonia
- Clinical characteristics (axis 1), which include age at onset, body distribution, temporal pattern, and associated features
- Etiology (axis 2), which includes nervous system pathology and inheritance.
- Isolated dystonia (dystonia alone or dystonia with tremor)
- Combined dystonia (dystonia with other movement disorders)
- Complex dystonia (dystonia with other symptoms).
- Drug-induced acquired dystonia
- Pseudodystonia due to cervical instability
- Status dystonicus
- Multiple neurometabolic disorders, such as glutaric aciduria type I
- Acute bilirubin encephalopathy.
Citations
van Egmond ME, Kuiper A, Eggink H, et al. Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):774-81.[Abstract][Full Text]
American Academy for Cerebral Palsy and Developmental Medicine. Cerebral palsy and dystonia. Apr 2024 [internet publication].[Full Text]
1. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol. 1998;78:1-10.[Abstract]
2. Wirth T, Tranchant C, Drouot N, et al. Increased diagnostic yield in complex dystonia through exome sequencing. Parkinsonism Relat Disord. 2020 May;74:50-6.[Abstract]
3. Holla VV, Neeraja K, Stezin A, et al. Utility of clinical exome sequencing in dystonia: a single-center study from India. J Mov Disord. 2022 May;15(2):156-61.[Abstract][Full Text]
4. Geyer HL, Bressman SB. The diagnosis of dystonia. Lancet Neurol. 2006 Sep;5(9):780-90.[Abstract]
5. Obese JA. General concepts. In: Fernández-Alvarez E, Aicardi J, eds. Movement disorders in children. London: Mac Keith Press; 2001:1-23.
6. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73.[Abstract][Full Text]
7. van Egmond ME, Kuiper A, Eggink H, et al. Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):774-81.[Abstract][Full Text]
8. Sanger TD. Pathophysiology of pediatric movement disorders. J Child Neurol. 2003 Sep;18 Suppl 1:S9-24.[Abstract]
9. Kamal N, Bhat DP, Carrick E. Dopa-responsive dystonia (Segawa syndrome). Indian Pediatr. 2006 Jul;43(7):635-8.[Abstract][Full Text]
10. Jan MM. Misdiagnosis in children with dopa-responsive dystonia. Pediatr Neurol. 2004 Oct;31(4):298-303.[Abstract]
11. Mink JW. Functional anatomy of the basal ganglia. In: Stacy MA, ed. Handbook of dystonia. New York, NY: Informa Healthcare; 2012.
12. Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson And Movement Disorder Society task force. Mov Disord. 2016 Apr;31(4):436-57.[Abstract]
13. Lange LM, Gonzalez-Latapi P, Rajalingam R, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society task force - an update. Mov Disord. 2022 May;37(5):905-35.[Abstract][Full Text]
14. Balint B, Bhatia KP. Isolated and combined dystonia syndromes - an update on new genes and their phenotypes. Eur J Neurol. 2015 Apr;22(4):610-7.[Abstract]
15. Ozelius L, Kramer PL, Moskowitz CB, et al. Human gene torsin dystonia located on chromosome 9q32-q34. Neuron. 1989 May;2(5):1427-34.[Abstract]
16. Rostasy K, Augood SJ, Hewett JW, et al. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis. 2003 Feb;12(1):11-24.[Abstract]
17. Asmus F, Langseth A, Doherty E, et al. "Jerky" dystonia in children: spectrum of phenotypes and genetic testing. Mov Disord. 2009 Apr 15;24(5):702-9.[Abstract]
18. Müller B, Hedrich K, Kock N, et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet. 2002 Dec;71(6):1303-11.[Abstract][Full Text]
19. Chen DH, Méneret A, Friedman JR, et al. ADCY5-related dyskinesia: broader spectrum and genotype-phenotype correlations. Neurology. 2015 Dec 8;85(23):2026-35.[Abstract][Full Text]
20. Heinzen EL, Swoboda KJ, Hitomi Y, et al. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet. 2012 Sep;44(9):1030-4.[Abstract][Full Text]
21. Brashear A, Mink JW, Hill DF, et al. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012 Nov;54(11):1065-7.[Abstract][Full Text]
22. Sweney MT, Silver K, Gerard-Blanluet M, et al. Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome. Pediatrics. 2009 Mar;123(3):e534-41.[Abstract]
23. Wang JL, Cao L, Li XH, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain. 2011 Dec;134(Pt 12):3493-501.[Abstract][Full Text]
24. Ebrahimi-Fakhari D, Saffari A, Westenberger A, et al. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain. 2015 Dec;138(Pt 12):3476-95.[Abstract][Full Text]
25. Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain. 2015 Dec;138(Pt 12):3567-80.[Abstract][Full Text]
26. Bruno MK, Lee HY, Auburger GW, et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology. 2007 May 22;68(21):1782-9.[Abstract]
27. Suls A, Dedeken P, Goffin K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain. 2008 Jul;131(Pt 7):1831-44.[Abstract][Full Text]
28. Pearl PL, Capp PK, Novotny EJ, et al. Inherited disorders of neurotransmitters in children and adults. Clin Biochem. 2005 Dec;38(12):1051-8.[Abstract]
29. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. 1994 Nov;8(3):236-42.[Abstract]
30. Ludecke B, Dworniczak B, Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet. 1995 Jan;95(1):123-5.[Abstract]
31. Pearson TS, Gupta N, San Sebastian W, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat Commun. 2021 Jul 12;12(1):4251.[Abstract][Full Text]
32. Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther. 2022 Feb 2;30(2):509-18.[Abstract][Full Text]
33. Keam SJ. Eladocagene exuparvovec: first approval. Drugs. 2022 Sep;82(13):1427-32.[Abstract]
34. Kurian MA, Zhen J, Cheng S-Y, et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest. 2009 Jun;119(6):1595-603.[Abstract][Full Text]
35. Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol. 2011 Jan;10(1):54-62.[Abstract][Full Text]
36. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013 Feb 7;368(6):543-50.[Abstract][Full Text]
37. Jacobsen JC, Wilson C, Cunningham V, et al. Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. J Inherit Metab Dis. 2016 Mar;39(2):305-8.[Abstract]
38. Rath M, Korenke GC, Najm J, et al. Exome sequencing results in identification and treatment of brain dopamine-serotonin vesicular transport disease. J Neurol Sci. 2017 Aug 15;379:296-7.[Abstract]
39. Kuiper A, Eggink H, Tijssen MA, et al. Neurometabolic disorders are treatable causes of dystonia. Rev Neurol (Paris). 2016 Aug - Sep;172(8-9):455-64.[Abstract]
40. Boy N, Mühlhausen C, Maier EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017 Jan;40(1):75-101.[Abstract]
41. Jinnah HA, Visser JE, Harris JC, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain. 2006 May;129(Pt 5):1201-17.[Abstract][Full Text]
42. Tanji K, Kunimatsu T, Vu TH, et al. Neuropathological features of mitochondrial disorders. Semin Cell Dev Biol. 2001 Dec;12(6):429-39.[Abstract]
43. Heimer G, Kerätär JM, Riley LG, et al. MECR mutations cause childhood-onset dystonia and optic atrophy, a mitochondrial fatty acid synthesis disorder. Am J Hum Genet. 2016 Dec 1;99(6):1229-44.[Abstract][Full Text]
44. Schwartz CE, May MM, Carpenter NJ, et al. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet. 2005 Jul;77(1):41-53.[Abstract][Full Text]
45. Stockler-Ipsiroglu S, van Karnebeek CD. Cerebral creatine deficiencies: a group of treatable intellectual developmental disorders. Semin Neurol. 2014 Jul;34(3):350-6.[Abstract]
46. Alfadhel M, Tabarki B. SLC19A3 gene defects sorting the phenotype and acronyms: review. Neuropediatrics. 2018 Apr;49(2):83-92.[Abstract]
47. Ebrahimi-Fakhari D, Hildebrandt C, Davis PE, et al. The spectrum of movement disorders in childhood-onset lysosomal storage diseases. Mov Disord Clin Pract. 2018 Mar-Apr;5(2):149-55.[Abstract][Full Text]
48. Mignot C, Doummar D, Maire I, et al. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006 Jan;28(1):39-48.[Abstract]
49. Schneider SA, Dusek P, Hardy J, et al. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol. 2013 Jan;11(1):59-79.[Abstract][Full Text]
50. Lee JH, Yun JY, Gregory A, et al. Brain MRI pattern recognition in neurodegeneration with brain iron accumulation. Front Neurol. 2020 Sep 10;11:1024.[Abstract][Full Text]
51. Quadri M, Federico A, Zhao T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012 Mar 9;90(3):467-77.[Abstract][Full Text]
52. Tuschl K, Clayton PT, Gospe SM Jr, et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012 Mar 9;90(3):457-66.[Abstract][Full Text]
53. Tuschl K, Meyer E, Valdivia LE, et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat Commun. 2016 May 27;7:11601.[Abstract][Full Text]
54. Simons C, Wolf NI, McNeil N, et al. A de novo mutation in the beta-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet. 2013 May 2;92(5):767-73.[Abstract][Full Text]
55. Simons C, Griffin LB, Helman G, et al. Loss-of-function alanyl-tRNA synthetase mutations cause an autosomal-recessive early-onset epileptic encephalopathy with persistent myelination defect. Am J Hum Genet. 2015 Apr 2;96(4):675-81.[Abstract][Full Text]
56. Cacciagli P, Sutera-Sardo J, Borges-Correia A, et al. Mutations in BCAP31 cause a severe X-linked phenotype with deafness, dystonia, and central hypomyelination and disorganize the Golgi apparatus. Am J Hum Genet. 2013 Sep 5;93(3):579-86.[Abstract][Full Text]
57. Livingston JH, Crow YJ. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières syndrome and beyond. Neuropediatrics. 2016 Dec;47(6):355-60.[Abstract]
58. Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis. 2022 May;81(5):601-13.[Abstract][Full Text]
59. Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet. 2007 Oct;81(4):713-25.[Abstract][Full Text]
60. Grosso S, Lasorella G, Russo A, et al. Aicardi syndrome with favorable outcome: case report and review. Brain Dev. 2007 Aug;29(7):443-6.[Abstract]
61. Vanderver A, Prust M, Kadom N, et al. Early-onset Aicardi-Goutières syndrome: magnetic resonance imaging (MRI) pattern recognition. J Child Neurol. 2015 Sep;30(10):1343-8.[Abstract][Full Text]
62. Østergaard JR, Christensen T. Aicardi-Goutieres syndrome: neuroradiological findings after nine years of follow-up. Eur J Paediatr Neurol. 2004;8(5):243-6.[Abstract]
63. Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol. 1984 Jan;15(1):49-54.[Abstract]
64. Goutieres F. Aicardi-Goutieres syndrome. Brain Dev. 2005 Apr;27(3):201-6.[Abstract]
65. Edvardson S, Tian G, Cullen H, et al. Infantile neurodegenerative disorder associated with mutations in TBCD, an essential gene in the tubulin heterodimer assembly pathway. Hum Mol Genet. 2016 Nov 1;25(21):4635-48.[Abstract][Full Text]
66. Lenk GM, Szymanska K, Debska-Vielhaber G, et al. Biallelic mutations of VAC14 in pediatric-onset neurological disease. Am J Hum Genet. 2016 Jul 7;99(1):188-94.[Abstract][Full Text]
67. Kato M, Das S, Petras K, et al. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat. 2004 Feb;23(2):147-59.[Abstract]
68. Guerrini R, Moro F, Kato M, et al. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology. 2007 Jul 31;69(5):427-33.[Abstract]
69. Zech M, Boesch S, Maier EM, et al. Haploinsufficiency of KMT2B, encoding the lysine-specific histone methyltransferase 2B, results in early-onset generalized dystonia. Am J Hum Genet. 2016 Dec 1;99(6):1377-87.[Abstract][Full Text]
70. Meyer E, Carss KJ, Rankin J, et al. Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet. 2017 Feb;49(2):223-37.[Abstract]
71. Gorman KM, Meyer E, Kurian MA. Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B. Eur J Paediatr Neurol. 2018 Mar;22(2):245-56.[Abstract]
72. Ananth AL, Robichaux-Viehoever A, Kim YM, et al. Clinical course of six children with GNAO1 mutations causing a severe and distinctive movement disorder. Pediatr Neurol. 2016 Jun;59:81-4.[Abstract]
73. Danti FR, Galosi S, Romani M, et al. GNAO1 encephalopathy: broadening the phenotype and evaluating treatment and outcome. Neurol Genet. 2017 Mar 21;3(2):e143.[Abstract][Full Text]
74. Kortüm F, Das S, Flindt M, et al. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet. 2011 Jun;48(6):396-406.[Abstract][Full Text]
75. Ohba C, Shiina M, Tohyama J, et al. GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. Epilepsia. 2015 Jun;56(6):841-8.[Abstract][Full Text]
76. Hankø E, Hansen TW, Almaas R, et al. Bilirubin induces apoptosis and necrosis in human NT2-N neurons. Pediatr Res. 2005 Feb;57(2):179-84.[Abstract]
77. van der Linden H, Silveira-Moriyama L, van der Linden V, et al. Movement disorders in children with congenital Zika virus syndrome. Brain Dev. 2020 Nov;42(10):720-9.[Abstract]
78. Mohammad SS, Fung VS, Grattan-Smith P, et al. Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord. 2014 Oct;29(12):1539-42.[Abstract]
79. American Academy for Cerebral Palsy and Developmental Medicine. Cerebral palsy and dystonia. Apr 2024 [internet publication].[Full Text]
80. Moreno-De-Luca A, Millan F, Pesacreta DR, et al. Molecular diagnostic yield of exome sequencing in patients with cerebral palsy. JAMA. 2021 Feb 2;325(5):467-75.[Abstract][Full Text]
81. Bredenkamp JK, Maceri DR. Inflammatory torticollis in children. Arch Otolaryngol Head Neck Surg. 1990 Mar;116(3):310-3.[Abstract]
82. Queensland Ambulance Service. Clinical practice guidelines: medical/acute dystonic reaction. 2020 [internet publication].[Full Text]
83. Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005 Nov;252(11):1299-306.[Abstract]
84. Bergman I, Steeves M, Burckart G, et al. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. J Pediatr. 1991 Oct;119(4):644-9.[Abstract]
85. Beltran RS, Coker SB. Transient dystonia of infancy, a result of intrauterine cocaine exposure? Pediatr Neurol. 1995 May;12(4):354-6.[Abstract]
86. Gokhale SG, Panchakshari MB. Maternal medication causing drug dystonia in a newborn: placental transfer of drugs. J Matern Fetal Neonatal Med. 2004 Oct;16(4):215-7.[Abstract]
87. Shafrir Y, Levy Y, Beharab A, et al. Acute dystonic reaction to bethanechol: a direct acetylcholine receptor agonist. Dev Med Child Neurol. 1986 Oct;28(5):646-8.[Abstract]
88. Howrie DL, Rowley AH, Krenzelok EP. Benztropine-induced acute dystonic reaction. Ann Emerg Med. 1986 May;15(5):594-6.[Abstract]
89. Shafrir Y, Levy Y, Steinherz R. Acute dystonic reaction due to domperidone in an infant [in Hebrew]. Harefuah. 1986 Mar 2;110(5):237-8.[Abstract]
90. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics. 2006 Aug;118(2):746-52.[Abstract]
91. Meija NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005 Jan;20(1):86-9.[Abstract]
92. Angelini L, Zorzi G, Rumi V, et al. Transient paroxysmal dystonia in an infant possibly induced by cisapride. Ital J Neurol Sci. 1996 Apr;17(2):157-9.[Abstract]
93. Kawana S, Toyoshima Y, Tobise F, et al. Dystonic reaction following general anesthesia in a 2-month-old infant. Paediatr Anaesth. 2007 Sep;17(9):901-2.[Abstract]
94. Crosley CJ, Swender PT. Dystonia associated with carbamazepine administration: experience in brain-damaged children. Pediatrics. 1979 Apr;63(4):612-5.[Abstract]
95. Adams SB Jr, Flynn JM, Hosalkar HS, et al. Torticollis in an infant caused by hereditary muscle aplasia. Am J Orthop (Belle Mead NJ). 2003 Nov;32(11):556-8.[Abstract]
96. Caress JB, Nohria V, Fuchs H, et al. Torticollis acquired in late infancy due to a cerebellar gangliocytoma. Int J Pediatr Otorhinolaryngol. 1996 Jun;36(1):39-44.[Abstract]
97. Ekinci S, Karnak I, Tanyel FC. Infantile fibromatosis of the sternocleidomastoid muscle mimicking muscular torticollis. J Pediatr Surg. 2004 Sep;39(9):1424-5.[Abstract]
98. Lehwald N, Krausch M, Franke C, et al. Sandifer syndrome: a multidisciplinary diagnostic and therapeutic challenge. Eur J Pediatr Surg. 2007 Jun;17(3):203-6.[Abstract]
99. Dimaala J, Chaljub G, Oto A, et al. Odontoid osteomyelitis masquerading as a C2 fracture in an 18-month-old male with torticollis: CT and MRI features. Emerg Radiol. 2006 Jul;12(5):234-6.[Abstract]
100. Mukherjee S, Sharief N. Bacterial meningitis presenting as acute torticollis. Acta Paediatr. 2004 Jul;93(7):1005-6.[Abstract]
101. Kiblinger GD, Wallace BS, Hines M, et al. Spasmus nutans-like nystagmus is often associated with underlying ocular, intracranial, or systemic abnormalities. J Neuroophthalmol. 2007 Jun;27(2):118-22.[Abstract]
102. Nordli DR Jr, Kuroda MM, Hirsch LJ. The ontogeny of partial seizures in infants and young children. Epilepsia. 2001 Aug;42(8):986-90.[Abstract][Full Text]
103. Cataltepe SU, Barron TF. Benign paroxysmal torticollis presenting as "seizures" in infancy. Clin Pediatr (Phila). 1993 Sep;32(9):564-5.[Abstract]
104. Saini AG, Hassan I, Sharma K, et al. Status dystonicus in children: a cross-sectional study and review of literature. J Child Neurol. 2022 May;37(6):441-50.[Abstract]
105. Pierro MM, Bollea L, Di Rosa G, et al. Anoxic brain injury following near-drowning in children. Rehabilitation outcome: three case reports. Brain Inj. 2005 Dec;19(13):1147-55.[Abstract]
106. Garone G, Graziola F, Nicita F, et al. Prestatus and status dystonicus in children and adolescents. Dev Med Child Neurol. 2020 Jun;62(6):742-9.[Abstract][Full Text]
107. Goswami JN, Roy S, Patnaik SK. Pediatric dystonic storm: a hospital-based study. Neurol Clin Pract. 2021 Oct;11(5):e645-53.[Abstract][Full Text]
108. Mariotti P, Fasano A, Contarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord. 2007 May 15;22(7):963-8.[Abstract]
109. Teive HA, Munhoz RP, Souza MM, et al. Status dystonicus: study of five cases. Arq Neuropsiquiatr. 2005 Mar;63(1):26-9.[Abstract][Full Text]
110. Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain. 1998 Feb;121 (Pt 2):243-52.[Abstract][Full Text]
111. Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021 May;44(3):566-92.[Abstract][Full Text]
112. Prietsch V, de Baulny HO, Saudubray J-M. Emergency treatments. In: Fernandes J, ed. Inborn metabolic diseases. 4th ed. Heidelberg, Germany: Springer Medizin; 2006:71-8.
113. Zhou L, Chillag KL, Nigro MA. Hyperekplexia: a treatable neurogenetic disease. Brain Dev. 2002 Oct;24(7):669-74.[Abstract]
114. Fernández-Alvarez E. Prevalence of paediatric movement disorders. In: Fernández-Alvarez E, Arzimanoglou A, Tolosa E, eds. Paediatric movement disorders. Montrouge, France: John Libbey Eurotext; 2005:1-18.
115. Jethwa A, Mink J, Macarthur C, et al. Development of the hypertonia assessment tool (HAT): a discriminative tool for hypertonia in children. Dev Med Child Neurol. 2010 May;52(5):e83-7.[Abstract]
116. Sanger TD. Toward a definition of childhood dystonia. Curr Opin Pediatr. 2004 Dec;16(6):623-7.[Abstract]
117. Fernández-Alvarez E. Dystonia. The paediatric perspective. Eur J Neurol. 2010 Jul;17 Suppl 1:46-51.[Abstract]
118. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010 Aug 15;25(11):1538-49.[Abstract]
119. Randby H, Salvador CL, Oppebøen M, et al. Dopa-responsive dystonia [in Norweigan]. Tidsskr Nor Laegeforen. 2018 Nov 27;138(19).[Abstract][Full Text]
120. Jinnah HA, Albanese A, Bhatia KP, et al. Treatable inherited rare movement disorders. Mov Disord. 2018 Jan;33(1):21-35.[Abstract][Full Text]
121. Brandsma R, van Egmond ME, Tijssen MAJ, et al. Diagnostic approach to paediatric movement disorders: a clinical practice guide. Dev Med Child Neurol. 2021 Mar;63(3):252-8.[Abstract][Full Text]
122. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES task force. Eur J Neurol. 2006 May;13(5):433-44.[Abstract]
123. Giffin N, Benton S, Goadsby PS. Benign paroxysmal torticollis of infancy; four new cases and linkage to CACNA1A mutation. Dev Med Child Neurol. 2002 Jul;44(7):490-3.[Abstract]
124. Assmann B, Surtees R, Hoffmann GF. Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol. 2003;54 Suppl 6:S18-24.[Abstract]
125. Kumar KR, Davis RL, Tchan MC, et al. Whole genome sequencing for the genetic diagnosis of heterogenous dystonia phenotypes. Parkinsonism Relat Disord. 2019 Dec;69:111-8.[Abstract][Full Text]
126. Pozojevic J, Beetz C, Westenberger A. The importance of genetic testing for dystonia patients and translational research. J Neural Transm (Vienna). 2021 Apr;128(4):473-81.[Abstract][Full Text]
127. Dzinovic I, Škorvánek M, Necpál J, et al. Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: a case series. Parkinsonism Relat Disord. 2021 Sep;90:73-8.[Abstract]
128. Graziola F, Garone G, Stregapede F, et al. Diagnostic yield of a targeted next-generation sequencing gene panel for pediatric-onset movement disorders: a 3-year cohort study. Front Genet. 2019 Oct 29;10:1026.[Abstract][Full Text]
129. Retterer K, Scuffins J, Schmidt D, et al. Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort. Genet Med. 2015 Aug;17(8):623-9.[Abstract][Full Text]
130. Dale RC, Grattan-Smith P, Nicholson M, et al. Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: a single-centre study. Dev Med Child Neurol. 2012 Jul;54(7):618-23.[Abstract][Full Text]
131. Fogel BL, Satya-Murti S, Cohen BH. Clinical exome sequencing in neurologic disease. Neurol Clin Pract. 2016 Apr;6(2):164-76.[Abstract][Full Text]
132. Kong SW, Lee IH, Liu X, et al. Measuring coverage and accuracy of whole-exome sequencing in clinical context. Genet Med. 2018 Dec;20(12):1617-26.[Abstract][Full Text]
133. Dai P, Honda A, Ewans L, et al. Recommendations for next generation sequencing data reanalysis of unsolved cases with suspected Mendelian disorders: a systematic review and meta-analysis. Genet Med. 2022 Aug;24(8):1618-29.[Abstract][Full Text]
134. Willemse J. Benign idiopathic dystonia with onset in the first year of life. Dev Med Child Neurol. 1986 Jun;28(3):355-60.[Abstract]
135. Deonna TW, Ziegler AL, Nielsen J. Transient idiopathic dystonia in infancy. Neuropediatrics. 1991 Nov;22(4):220-4.[Abstract]
136. Deonna T, Martin D. Benign paroxysmal torticollis in infancy. Arch Dis Child. 1981 Dec;56(12):956-9.[Abstract][Full Text]
137. Dunn DW, Snyder CH. Benign paroxysmal vertigo of childhood. Am J Dis Child. 1976 Oct;130(10):1099-100.[Abstract]
138. Do TT. Congenital muscular torticollis: current concepts and review of treatment. Curr Opin Pediatr. 2006 Feb;18(1):26-9.[Abstract]
139. de Chalain TM, Park S. Torticollis associated with positional plagiocephaly: a growing epidemic. J Craniofac Surg. 2005 May;16(3):411-8.[Abstract]
140. Tien YC, Su JY, Lin GT, et al. Ultrasonographic study of the coexistence of muscular torticollis and dysplasia of the hip. J Pediatr Orthop. 2001 May-Jun;21(3):343-7.[Abstract]
141. Snyder EM, Coley BD. Limited value of plain radiographs in infant torticollis. Pediatrics. 2006 Dec;118(6):e1779-84.[Abstract]
142. Parikh SN, Crawford AH, Choudhury S. Magnetic resonance imaging in evaluation of infantile torticollis. Orthopedics. 2004 May;27(5):509-15.[Abstract]
143. Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003 Mar;10(1):68-79.[Abstract]
144. Bennett LB, Roach ES, Bowcock AM. A locus for paroxysmal kinesigenic dyskinesia maps to human chromosome 16. Neurology. 2000 Jan 11;54(1):125-30.[Abstract]
145. Cuenca-Leon E, Cormand B, Thomson T, et al. Paroxysmal kinesigenic dyskinesia and generalized seizures: clinical and genetic analysis in a Spanish pedigree. Neuropediatrics. 2002 Dec;33(6):288-93.[Abstract]
146. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct;38(4):571-9.[Abstract]
147. Lee HY, Xu Y, Huang Y, et al. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet. 2004 Dec 15;13(24):3161-70.[Abstract][Full Text]
148. Silver K, Andermannn F. Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment. Neurology. 1993 Jan;43(1):36-41.[Abstract]
149. Fraioli B, Guglielmi G, Baldassarre L. Clinical study of dantrolene sodium in the treatment of spastic and dystonic syndromes [in Italian]. Riv Neurol. 1976 Jul-Aug;46(4):333-50.[Abstract]
150. Nomura Y, Ikeuchi T, Tsuji S, et al. Two phenotypes and anticipation observed in Japanese cases with early onset torsion dystonia (DYT1) - pathophysiological consideration. Brain Dev. 2000 Sep;22 Suppl 1:S92-101.[Abstract]
151. Bianca S, Bianca M. A new deletion in autosomal dominant guanosine triphosphate cyclohydrolase I deficiency gene - Segawa disease. J Neural Transm (Vienna). 2006 Feb;113(2):159-62.[Abstract]
152. Bräutigam C, Steenbergen-Spanjers GC, Hoffmann GF, et al. Biochemical and molecular genetic characteristics of the severe form of thyrosine hydroxylase deficiency. Clin Chem. 1999 Dec;45(12):2073-8.[Abstract][Full Text]
153. Hoffmann GF, Assmann B, Brautigam C, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol. 2003;54 Suppl 6:S56-65.[Abstract]
154. Diepold K, Schutz B, Rostasy K, et al. Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections. Mov Disord. 2005 Jun;20(6):764-7.[Abstract]
155. Lopez-Laso E, Camino R, Mateos ME, et al. Dopa-responsive infantile hypokinetic rigid syndrome due to dominant guanosine triphosphate cyclohydrolase 1 deficiency. J Neurol Sci. 2007 May 15;256(1-2):90-3.[Abstract]
156. Saint Hilaire MH, Burke RE, Bressman SB, et al. Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology. 1991 Feb;41(2 (Pt 1)):216-22.[Abstract]
157. Hoon AH Jr, Reinhardt EM, Kelley RI, et al. Brain magnetic resonance imaging in suspected extrapyramidal cerebral palsy: observations in distinguishing genetic-metabolic from acquired causes. J Pediatr. 1997 Aug;131(2):240-5.[Abstract]
158. O'Suilleabhain P, Dewey RB Jr. Movement disorders after head injury: diagnosis and management. J Head Trauma Rehabil. 2004 Jul-Aug;19(4):305-13.[Abstract]
159. Alkhani A, Bohlega S. Unilateral pallidotomy for hemidystonia. Mov Disord. 2006 Jun;21(6):852-5.[Abstract]
160. Kostic VS, Covickovic-Sternic N, Svetel-Stojanovic M, et al. Delayed-onset dystonia due to asphyxia in the perinatal period [in Serbian]. Srp Arh Celok Lek. 1997 Mar-Apr;125(3-4):84-8.[Abstract]
161. Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):59-67.[Abstract][Full Text]
162. Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol. 2006 Jun;33(2):387-410.[Abstract]
163. Strauss KA, Puffenberger EG, Robinson DL, et al. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet. 2003 Aug 15;121C(1):38-52.[Abstract]
164. Kölker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I - revised recommendations. J Inherit Metab Dis. 2011 Jun;34(3):677-94.[Abstract][Full Text]
165. Page T, Bakay B, Nissinen E. Hypoxanthine-guanine phosphoribosyltransferase variants: correlation of clinical phenotype with enzyme activity. J Inherit Metab Dis. 1981;4(4):203-6.[Abstract]
166. Jinnah HA, Harris JC, Nyhan WL. The spectrum of mutations causing HPRT deficiency: an update. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1153-60.[Abstract]
167. Brismar J, Brismar G, Coates R, et al. Increased density of the thalamus on CT scans in patients with GM2 gangliosidoses. AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):125-30.[Abstract]
168. Yamada E, Matsumoto M, Hazaa F, et al. Two siblings, including a fetus, with Tay-Sachs disease. Acta Pathol Jpn. 1981 Nov;31(6):1053-61.[Abstract]
169. Carrozzo R, Piemonte F, Tessa A, et al. Infantile mitochondrial disorders. Biosci Rep. 2007 Jun;27(1-3):105-12.[Abstract]
170. Carrozzo R, Dionisi-Vici C, Steuerwald U, et al. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain. 2007 Mar;130(Pt 3):862-74.[Abstract][Full Text]
171. McFarland R, Chinnery PF, Blakely EL, et al. Homoplasmy, heteroplasmy, and mitochondrial dystonia. Neurology. 2007 Aug 28;69(9):911-6.[Abstract]
172. Filosto M, Tomelleri G, Tonin P, et al. Neuropathology of mitochondrial diseases. Biosci Rep. 2007 Jun;27(1-3):23-30.[Abstract]
173. Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr. 2003 Dec;15(6):572-7.[Abstract]
174. Rao C, Murthy V, Hedge R, et al. Hallervorden Spatz disease. Indian J Pediatr. 2003 Jun;70(6):513-4.[Abstract]
175. Ching KH, Westaway SK, Gitschier J, et al. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology. 2002 Jun 11;58(11):1673-4.[Abstract]
176. Ostergaard JR, Christensen T, Hansen KN. In vivo diagnosis of Hallervorden-Spatz disease. Dev Med Child Neurol. 1995 Sep;37(9):827-33.[Abstract]
177. Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur J Paediatr Neurol. 2002;6(5):243-7.[Abstract]
178. Matarin MM, Singleton AB, Houlden H. PANK2 gene analysis confirms genetic heterogeneity in neurodegeneration with brain iron accumulation (NBIA) but mutations are rare in other types of adult neurodegenerative disease. Neurosci Lett. 2006 Oct 23;407(2):162-5.[Abstract]
179. Hersheson J, Mencacci NE, Davis M, et al. Mutations in the autoregulatory domain of beta-tubulin 4a cause hereditary dystonia. Ann Neurol. 2013 Apr;73(4):546-53.[Abstract][Full Text]
180. Kabakuş N, Kurt A. Sandifer syndrome: a continuing problem of misdiagnosis. Pediatr Int. 2006 Dec;48(6):622-5.[Abstract]
181. Smith DE, Fitzgerald K, Stass-Isern M, et al. Electroretinography is necessary for spasmus nutans diagnosis. Pediatr Neurol. 2000 Jul;23(1):33-6.[Abstract]
182. Vigevano F, Bartuli A. Infantile epileptic syndromes and metabolic etiologies. J Child Neurol. 2002 Dec;17 Suppl 3:3S9-13.[Abstract]
183. Fenichel GM. Paroxysmal disorders. In: Fenichel GM, ed. Clinical pediatric neurology - a signs and symptoms approach. Philadelphia, PA: Elsevier Saunders; 2019:1-49.
Key Articles
Other Online Resources
Referenced Articles
Sign in to access our clinical decision support tools